New Rhein Healthcare Investors, LLC
Venture capitalPhiladelphia · Series A–Late Stage · 7 people tracked
Investment thesis
New Rhein Healthcare Investors is a venture capital and growth equity firm that invests in pharmaceutical and healthcare companies developing novel applications of existing drugs, including new formulations and therapeutic indications. The firm's portfolio has included companies in Alzheimer's disease, eye care, respiratory conditions, and oncology diagnostics.
Team · 7 people
from the firm's websiteFrequently asked questions
- What stage does New Rhein Healthcare Investors, LLC invest at?
- New Rhein Healthcare Investors, LLC invests at the Series A, Series B, Series C, Late Stage stages.
- What sectors does New Rhein Healthcare Investors, LLC focus on?
- New Rhein Healthcare Investors, LLC focuses on Biotech, Medical Devices.
- Where is New Rhein Healthcare Investors, LLC located?
- New Rhein Healthcare Investors, LLC is headquartered in Philadelphia, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
EQT Life Sciences is one of Europe's largest and most experienced life sciences investors, focusing on innovative companies developing therapeutics, medical devices, diagnostics, and healthtech globally. The firm has raised approximately 3.5 billion euros across 12 private funds and 3 investment strategies over its 30-year history.